# **Nocturnal** enuresis in children

## When to treat, when to refer

ANIRUDDH V. DESHPANDE MB BS. MS. FRACS. PhD PATRINA H.Y. CALDWELL FRACP. PhD

Nocturnal enuresis is common and has the potential to have a significant negative psychosocial impact on children. Most children with enuresis can be successfully treated by GPs. This article aims to assist GPs with the initial treatment of enuresis using sound principles of assessment and triaging.

octurnal enuresis (bedwetting) is common in schoolaged children. It affects one in five children at 5 years of age and about one in 10 children at 10 years of age.1 Children with enuresis can have strong feelings of shame, guilt and failure, and a sense of being different to others. Often children with enuresis will avoid social activities. The negative impact seems to be greater in older children and in girls.<sup>2</sup> In addition to the emotional costs, there are the financial costs to parents and/or carers, as well as time and effort in cleaning. One in seven children will spontaneously become dry every year and treatment should be offered to help others with significant enuresis achieving dryness sooner.

#### MedicineToday 2019; 20(6): 63-67

Dr Deshpande is a Staff Specialist, Department of Paediatric Urology and Surgery. John Hunter Children's Hospital, Newcastle: Paediatric Urologist/Surgeon. Children's Hospital at Westmead, Sydney; and Member of Priority Research Centre, GrowupWell, Faculty of Health and Medicine, University of Newcastle. Associate Professor Caldwell is Senior Staff Specialist, Sydney Children's Hospital Network; and Discipline of Child and Adolescent Health, The University of Sydney, Sydney, NSW.

SERIES EDITOR: Dr Chris Elliot BMed(Hons), FRACP General and Developmental Paediatrician, St George Hospital, Sydney; and Conjoint Lecturer, School of Women's and Children's Health, UNSW Sydney, NSW.



#### What causes bedwetting?

The three main physiological factors in enuresis are:

- defective sleep arousal
- nocturnal polyuria
- urinary bladder factors (e.g. lack of inhibition of bladder emptying during sleep, reduced bladder capacity or bladder overactivity).

The contribution and pathogenesis of these factors vary from child to child. Enuresis is more common in children with:

- a positive family history large UK study found the odds ratios for severe nocturnal enuresis were 3.6 and 1.9 times higher if a mother or father, respectively, had a history of enuresis3
- sleep-disordered breathing in children with enuresis and obstructive sleep apnoea from adenotonsillar hypertrophy, the enuresis resolves in up to half after appropriate treatment
- obesity
- attention deficit hyperactivity disorder (ADHD)
- autistic spectrum disorder
- developmental delay and physical or intellectual disability.

#### What type of enuresis is it?

The initial assessment of the child with nocturnal enuresis should determine:

- if nocturnal enuresis is monosymptomatic (MNE) or nonmonosymptomatic (NMNE [for definitions see Table])<sup>4</sup>
- if it is primary or secondary
- the severity of enuresis and of any other symptoms.

The Flowchart outlines how to classify the type and severity of nocturnal enuresis. Pathogenic differences exist between the different groups. For example, children with NMNE, secondary enuresis and more severe symptoms are less likely to respond to

### **TABLE.** USEFUL DEFINITIONS RECOMMENDED BY THE INTERNATIONAL CHILDREN'S CONTINENCE SOCIETY<sup>4</sup>

Term	Definition
Urinary incontinence	Involuntary leakage of urine
Continuous incontinence	Constant day and night urinary leakage
Intermittent incontinence	Urinary leakage in discrete amounts
Daytime incontinence	Intermittent incontinence while awake
Enuresis/nocturnal enuresis	Intermittent urinary incontinence exclusively during sleep
Monosymptomatic	Enuresis with no daytime lower urinary tract symptoms
Nonmonosymptomatic	Enuresis as well as other daytime lower urinary tract symptoms
Primary	Never been dry at night for more than 6 months
Secondary	Have previously been dry at night for at least 6 months
Nocturnal polyuria	Nocturnal urine output exceeding 130% of expected bladder capacity for the child's age
Nocturia	The need to wake at night to void (not uncommon in school-aged children)
Bladder bowel dysfunction	Concomitant bladder and bowel disturbances of clinical significance and relevance. It can be subcategorised into lower urinary tract dysfunction and bowel dysfunction
Increased daytime voiding frequency	Voiding ≥8 times per day
Decreased daytime voiding frequency	Voiding ≤3 times per day
Constipation	Rome IV criteria: two or more of the following in a child with a developmental age of 4 years or older. Must include:  • two or fewer defaecations per week  • at least one episode of faecal incontinence per week  • history of retentive posturing or excessive volitional stool retention  • history of painful or hard bowel movements  • presence of a large faecal mass in the rectum  • history of large diameter stools that can obstruct the toilet
Faecal incontinence (this should replace the term 'encopresis')	Can be constipation-associated faecal incontinence (most common) or nonretentive faecal incontinence
Expected bladder capacity	(Age + 1) x 30 mL (up to max 400 mL)

first-line treatment, are more complicated to manage and take longer to achieve dryness.

#### **Clinical assessment**

It is important to allow sufficient time for a thorough assessment and to formulate a plan with the child and parents.

#### History

- Family history of enuresis or urinary incontinence.
- Daytime urinary symptoms, such as:
  - frequency and severity of wetting
  - urgency
- voiding frequency more than eight times a day

- dysuria or pain
- holding manoeuvres.
- Bowel history. Enuresis is often associated with chronic constipation and faecal incontinence. In those with constipation and enuresis, enuresis has been shown to resolve in up to two-thirds of children after the constipation is successfully treated.<sup>5</sup>
- Fluid intake and diet. This may impact on bladder function (fluid restriction may reduce the size of the bladder, and fluid loading in the evening may increase the risk of bedwetting) and constipation.
- Sleep history. Children with enuresis are more difficult to arouse than their peers, have more fragmented sleep and have higher levels of daytime sleepiness. There is also a higher prevalence of sleep-disordered breathing and the child may need assessment for adenotonsillar hypertrophy.
- General health, including developmental delay, ADHD, oppositional defiant disorder and other mental health history. Enuresis may be a symptom of an undiagnosed medical condition such as diabetes or kidney disease. The presence of ADHD, autistic spectrum disorder or other physical, psychological or behavioural disabilities can complicate management and signal the need for greater input and support.
- Home, school and family situation.
   This may clarify the impact of the enuresis on the child and influence the choice of treatments.

#### **Physical examination**

- An abdominal examination.
- A brief neurological examination, including deep tendon reflexes, anal reflex, lower limb tone and examination of the back for signs of spinal lesions.
- An examination of the perineum and genitalia.

#### **Investigations**

- Urinalysis with or without urine culture.
- Bladder diary (frequency and volume chart, which can be downloaded online at: www.neresourcekit.com.au). A bladder diary for 48 hours provides objective data and helps to detect children with NMNE and those needing further evaluation. Practitioners should look for abnormalities in amount and distribution of fluid intake, daytime frequency, daytime leakage, severe urgency and nocturnal urine production.
- Renal ultrasound and postvoid residual assessment. A renal and bladder ultrasound is only indicated in cases of refractory enuresis or NMNE. Noninvasive uroflowmetry and postvoid residual assessment are available in some specialised bladder and continence clinics, which provide additional information for children with treatment resistance and/or those with severe associated daytime urinary symptoms.


#### When to refer early

Some children with nocturnal enuresis will require referral to, and management by, a specialist urologist and/or a multidisciplinary team, and some cases should be fast tracked. Indications for early referral are listed in Box 1.

#### **Initial management**

Initial management of enuresis consists of conservative measures aimed at rehabilitation of the lower urinary tract and bowel function (i.e. standard urotherapy). 4,6,7 This includes the following:

- Provide information and demystification. Explain about normal function and differences in the child's condition.
- Give instructions in establishing optimal micturition. Explain about the importance of regular voiding, proper voiding posture, avoidance of



voiding postponement and regular bowel habits. Encourage regular voiding during the day and void before bed. Voiding postponement may reduce the child's awareness of bladder sensations and their

- need to void. Encourage or teach relaxed voiding to optimise bladder emptying and storage.
- Establish guidelines for diet and fluid intake. Ensure patient is drinking adequately for optimal bladder

#### 1. RED FLAGS FOR EARLY REFERRAL OF THE CHILD WITH ENURESIS TO A **SPECIALIST**

- · True and continuous urinary leakage. May suggest a neurogenic or structural anomaly that needs intervention.
- · Children whose psychosocial wellbeing is at risk due to the urinary incontinence, including adolescents and children with psychological problems. These children should be fast tracked to a multidisciplinary approach to care. Older girls seem to be most at risk.
- · Refractory incontinence (i.e. treatment failure after six months). This is classified as complicated urinary incontinence.
- · A history of recurrent urinary tract infections.
- · Severe daytime symptoms.
- · Known or suspected physical or neurological problems.
- · Comorbid conditions such as faecal incontinence or diabetes.
- · Significant attention, developmental, behavioural or emotional problems.
- · Family problems or vulnerabilities.

function (fluid restriction may reduce the size of the bladder and fluid loading in the evening may increase the risk of bedwetting) and avoiding caffeinated drinks.

- Document symptoms and voiding habits. Use bladder diaries, frequency and volume charts and/or mobile apps.
- Ensure normal bowel habits. Treat constipation and ensure daily bowel movements passing normal consistency stools without straining. Note that some children with NMNE have remission of daytime symptoms when bowel problems are resolved.
- Support and encouragement. Ensure regular follow up with the caregiver and treating team. Information sheets and other useful tools can be downloaded from www. neresourcekit.com.au (see Box 2).

#### Managing children with monosymptomatic enuresis

For young children who are not bothered by the enuresis, active treatment may not be warranted. Spontaneous resolution rate of MNE is 15% per year. For younger children, star charts and rewards may help by providing incentives for rewarding the child for doing the right thing (such as drinking more during the day, reducing bedtime drinks and getting out of bed to void if they wake at night).7

#### Managing children with nonmonosymptomatic enuresis

In children with NMNE, treatment should target bladder function first as it can impact on both daytime and night-time wetting.6 Once these symptoms are resolved, it is easier to address the enuresis.

#### **Treatment**

#### **Alarm training**

Enuresis alarms train the child to wake to void when their bladder is full and hold on when they do not need to void during the night. The enuresis alarm detects when the child wets and emits a noise or vibration, alerting that the child has wet. When the alarm sounds, the child needs to wake and try and void in the toilet (even if they do not feel they need to void). Often children do not wake to the sound of the alarm (even if the rest of the family does). Parents need to wake the child if the child is unable to wake themselves. Alarm training takes two to three months. The child should continue alarm therapy until they have had 14 consecutive dry nights.

If relapse occurs, repeating alarm training will often produce a good response. For further tips, refer to the following website:www.neresourcekit.com.au. Alarm therapy needs commitment from both the child and family, as well as assistance from supportive and knowledgeable healthcare professionals.

#### **Desmopressin**

Desmopressin is an antidiuretic, a synthetic analogue of the hormone

#### 2. USEFUL LINKS AND RESOURCES FOR INITIATING TREATMENT OF **NOCTURNAL ENURESIS**

- The Nocturnal Enuresis Resource Kit (2nd edition). A tool for healthcare professionals
  - www.neresourcekit.com.au/ Nocturnal%20Enuresis%20 Resource%20Kit%20second%20 edition.pdf
- · NICE guidelines. Bedwetting in children and young people overview
  - https://pathways.nice.org.uk/ pathways/bedwetting-in-childrenand-young-people
- The Cochrane Library where several systematic reviews of various treatments for enuresis are located
  - www.cochranelibrary.com
- · The International Children's Continence Society (ICCS) website. Useful online course on paediatric incontinence
  - www.i-c-c-s.org
- Education and Resources for Improving Childhood Continence (ERIC) website
  - www.eric.org.uk
- The Continence Foundation of Australia website
  - www.continence.org.au
- The Australian Continence Exchange (ACE) website
  - www.continencexchange.org.au
- . The Sydney Children's Hospital Network: Kids Bladder Day Talks
  - www.schn.health.nsw.gov.au/ professionals/professionalresources/resources-for-healthcare-workers/kids-bladder-daytalks

vasopressin. Use of desmopressin in children with enuresis reduces overnight urine production; however, recent studies have pointed to an additional effect on the arousal mechanisms.8 About 70% of children with MNE will have a response to desmopressin, about 30% will be full responders and a further 40% will have a partial response with a reduction in the number of wet nights per week.1 A Cochrane review of desmopressin for enuresis concluded that desmopressin

rapidly reduced the number of wet nights per week, but the effect was not sustained after treatment stopped in most cases.9

Desmopressin is usually well tolerated, with adverse effects such as headaches, abdominal pain and emotional disturbance being uncommon. The most serious adverse effect reported for desmopressin is hyponatraemia, therefore, fluids should be restricted from one hour before medication until eight hours after. It is useful for short-term use, such as sleepovers or camps, or when alarm training is difficult or contraindicated (e.g. when family are not supportive).

Desmopressin is available on the PBS (authority required; streamlined) for primary nocturnal enuresis in patients 6 years of age or older who are refractory to an enuresis alarm or in whom an enuresis alarm is contraindicated. Desmopressin is available in the following formulations:

- sublingual wafer (melts), containing 60 mcg, 120 mcg or 240 mcg desmopressin
- tablet, containing 200 mcg desmopressin
- nasal spray, containing 10 mcg per actuation desmopressin. However, the nasal spray is not recommended because of a higher risk of adverse effects.

Melts are often used in primary schoolaged children because they are easy to take compared with tablets and are preferred by children under 12 years of age, which may enhance adherence.9,10 Although food interaction influences the bioavailability of desmopressin, melts have a smaller variance in plasma concentration with low food interaction, which may make the melts more suitable for younger children who may have a short interval between the evening meal and bedtime.<sup>11,12</sup> Furthermore, no water is needed to take the melt, so it is easier to comply with restriction of fluid intake.

The recommended dosage for children with enuresis is 200 to 400 mcg daily (for tablets) and 120 to 240 mcg daily (for melts)

taken about one hour before bedtime. Fluid intake must be limited (no more than one cup of water) from one hour before until eight hours after administration.

Relapse commonly occurs when desmopressin is ceased. However, structured withdrawal of desmopressin results in better relapse-free rates compared with abrupt withdrawal of desmopressin.<sup>13</sup>

#### **Desmopressin versus alarm therapy**

A Cochrane review comparing alarm and desmopressin therapies found that although at cessation of therapy there were generally no differences between the two in the short term, alarm therapy was more effective than desmopressin in the long term.10 Some studies report a higher initial attrition rate in families and children who use alarm therapy compared with those taking desmopressin.14

#### **Summary**

Nocturnal enuresis should be treated in children who show no signs of spontaneous resolution (by the time the child reaches primary school) and in those who report negative psychosocial impact. The type of enuresis (monosymptomatic or nonmonosymptomatic) should guide initial therapy. Children with suspected underlying urological or neurological causes or inadequate response after six months of treatment should be referred to a specialist. Bedwetting alarms and desmopressin (tablets or melts) are effective treatment options in appropriately selected patients and when offered in conjunction with successful urotherapy.

#### References

- 1. Caldwell PH, Deshpande AV, Von Gontard A. Management of nocturnal enuresis. BMJ 2013; 347: f6259.
- 2. Deshpande AV, Craig JC, Smith GH, Caldwell PH. Factors influencing quality of life in children with urinary incontinence. J Urology 2011; 186: 1048-1052
- 3. Von Gontard A. Heron J. Joinson C. Family history of nocturnal enuresis and urinary incontinence: results from a large epidemiological study. J Urology 2011; 185: 2303-2306.

- 4. Austin PF, Bauer SB, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the standardization committee of the International Children's Continence Society. Neurourol Urodyn 2016; 35: 471-481.
- 5. Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constination of childhood. Pediatrics 1997; 100(2 Pt 1): 228-232.
- 6. Franco I, von Gontard A, De Gennaro M. Evaluation and treatment of nonmonosymptomatic nocturnal enuresis: a standardization document from the International Children's Continence Society. J Pediatr Urol 2013; 9: 234-243.
- 7. Neveus T. Eggert P. Evans J. et al. Evaluation of and treatment for monosymptomatic enuresis: a standardization document from the International Children's Continence Society. J Urol 2010; 183: 441-447
- 8. Eggert P, Fritz A, Stecker B, Müller D. Desmopressin has an influence on the arousability of children with primary nocturnal enuresis. J Urol 2004; 171(6 Pt 2): 2586-2588.
- 9. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2002; (3): CD002112.
- 10. Glazener CM, Evans JH, Peto RE, Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev 2005; (2): CD002911.
- 11. De Guchtenaere A. Van Herzeele C. Raes A. et al. Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urology 2011: 185: 2308-2313.
- 12. De Bruyne P, De Guchtenaere A, Van Herzeele C, et al. Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis. Eur J Pediatr 2014; 173: 223-228. 13. Chua ME, Silangcruz JM, Chang SJ, et al. Desmopressin withdrawal strategy for pediatric enuresis: a meta-analysis. Pediatrics 2016; 138(1): e20160218.
- 14. Perrin N, Sayer L, While A. The efficacy of alarm therapy versus desmopressin therapy in the treatment of primary monosymptomatic nocturnal enuresis: a systematic review. Prim Health Care Res Dev 2015; 16: 21-31.

COMPETING INTERESTS: Dr Deshpande reports that he was a nominated party to an educational grant received by John Hunter Children's Hospital from Ferring Pharmaceuticals. Dr Caldwell None.